Endo quick associations Flashcards
DM drug that decreases the absorption of starch and disaccharides
Acarbose
DM drug that stimulates insulin release by inhibiting potassium ATP channel
sulfonylurease
meglitinides
DM drug that decreases hepatic gluconeogenesis
metformin
TZDs
DM drug mimics the action of GLP-1: lower glucagon, increased insulin, delays gastric emptying
GLP1 receptor agonists
DM drug that inhibits DPP-4 -> lower glucagon, increased insulin, delays gastric emptying
DPP4 inhibitors
DM drug that increases urinary elimination of sugar
SGLT2 inhibitors
Lactic acidosis is a rare But worrisome side effect
Metformin
Most common side effect is hypoglycemia
sulfonylurease
meglitinides
Oldest and cheapest to the oral non-insulin agents
sulfonylureas
metformin
First line for type II diabetes
metformin
Non-insulin drug not safe in setting of severe CHF
pioglitazone
TZDs
SGLT2
Non-insulin agent that should not be used in patients with renal dysfunction
SGLT2 inhibitors
caution - metformin
Non-insulin agents that are acceptable choices in patients with mild to moderate renal disease
TZDs
DPP4-inhibitors
Metformin
Non-insulin agents that increases risk for UTI and yeast infections
SGLT2-inhibitor
Patient presents with hypoglycemia labs reveal: Elevated insulin level Low C-peptide Low pro-insulin Sulfonylurea screen - negative
Excess Exogenous insulin